Merck & Co., Inc (NYSE: MRK) Continues Its Expansion With Planned Acquisition of Seagen Inc

Merck & Co., Inc (NYSE: MRK) has announced that it is in discussion to purchase Seagen Inc. and may reach an agreement as earlier as this month, according to people familiar with the matter. Merck to offer $200 per share to buy Seagen One of the sources stated that a sale price of around $200 per […]

Merck & Co. Inc (NYSE: MRK) To Move Forward with Plans To Purchase Seagen Inc

According to sources familiar with the matter, Merck & Co. Inc (NYSE: MRK) is moving forward with a possible acquisition of Seagen Inc.. This would be one of the biggest acquisitions of the year. Merck is in discussions to acquire Seagen to expand the cancer medication lineup Last week, The Wall Street Journal reported that […]

Why 2022 Could Open Gangbusters for Covid Stocks (AZN, OTLC, NVAX, PFE, MRNA, MRK, JNJ, BNTX)

If you think the pandemic is yesterday’s news, think again. One of the nation’s top doctors recently warned that the US could very soon start seeing as many as a million new Covid-19 cases every day due to the lightspeed spread of the new and recently emerging Omicron variant. Retiring NIH Director, Dr. Francis Collins, […]

Covid Stocks Set for Continued Interest on Global Omicron Surge (NVAX, OTLC, PFE, AZN, MRNA, MRK, JNJ, BNTX)

We are finally starting to get hard data on the Omicron variant of Covid-19 from its epicenter in Gauteng, South Africa. And that data, along with data on the variant from the UK, paint a picture of a flash fire spreading at unimaginable speed through populations likely already around the world. The major finding from […]

Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK)

With the spotlight firmly on Covid variants, it’s easy to lose sight of what will probably be the most important segment of the biopharma space over the next ten years: oncology. This is where the biggest success stories will be found. It’s where the largest revolutions will happen. It’s the epicenter of the most important […]

Therapeutics Candidates in Focus as Covid Data Heads Back to Front Burner (MRK, OTLC, PFE, JNJ, NVAX, BNTX, AZN, MRNA)

We are increasingly seeing signs that the pandemic is hardly over. The European Union is battling record case levels. Areas of the US are starting to see some similar dynamics. Hospitals in the developed world are beginning to fill back up with Covid patients. It’s a familiar pattern. This shouldn’t come as a total shock as […]

Biotech Investors Eye the Explosive PD1 Oncology Opportunity (MRK, OTLC, BMY, RHHBY, BGNE, GMAB)

The PD-1 blocker market has exploded into place as one of the most important and promising major biopharma oncology markets yet to appear. Immuno-oncology drugs that block the checkpoint PD-1 have been some of the most successful stories in the industry over recent years, launching blockbuster drugs like Opdivo and Keytruda – central assets from […]

The Next Biotech Winners After the Vaccine Bubble Burst (ATRX, INMB, DVAX, SAVA, ICPT, IMGN, IBB, MRK, AZN)

The Covid story is starting to change. And you can hear the popping sound in the vaccine space. The needle is “therapeutics”. The therapeutic route was thought to be tricky for this virus on the near-term time horizon, which fueled a massive tsunami into the vaccine stocks as large money managers thought they would be […]

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Signs a Licensing Deal with Merck & Co., Inc. (NYSE:MRK) Animal Health

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) completes a Definitive Agreement giving Merck & Co., Inc. (NYSE:MRK) Animal Health the rights to build up and distribute Aurinia’s patented nano-micellar cyclosporin ophthalmic solution (VOS) for treating dry eye disorders in dogs. In this agreement, the Aurinia will obtain an upfront payment and they could receive more recompense which will […]

Merck & Co., Inc. (NYSE:MRK) Falters Over Januvia Sales And Poor Q3 Results

Boston, MA 10/30/2013 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK) shares take a tumble following the poor weak earnings the company posted for the third quarter of 2013. The company continues to be troubled by patent issues with key drugs, which was further complicated by currency flip-flops. Both of the above primary drivers for the company […]

Merck & Co., Inc. (NYSE:MRK) To Save $2.5 Billion In Restructuring, Good News To Investors

Boston, MA 10/22/2013 (wallstreetpr) – After a seemingly good rally through last week, Merck & Co., Inc. (NYSE:MRK) eventually succumbed to the volatility in the health care sector to close the week on Friday, October 18, down by 1.06% to settle at $46.61. The global health care company is now undergoing restructuring efforts to see if it […]

Is Merck & Co., Inc. (NYSE:MRK) Still A Good Buy?

Boston, MA 10/21/2013 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK) has been struggling in the first half of 2013 on account of expiration some of the drug patents. It has embarked on an extensive restructuring program aimed at reducing costs by $2.5 billion. These reductions will be visible in 2014 and 2015. Maximum benefits are expected […]

Major Drug Makers; Johnson & Johnson (JNJ) and Eli Lilly (LLY) Database Collaboration – JNJ, PFE, BMY, MRK, ABT

On Monday, current three major drug makers Eli Lilly & Co. (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), and Merck & Co., Inc. (NYSE:MRK) have decided to collaborate on a database that will assist speed up the investigational drug testing process. The firm will each contribute to a database, which will be made of doctors, hospitals and […]